BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Piccoli GB, Consiglio V, Arena V, Pelosi E, Anastasios D, Ragni F, Fiori C, Cortese G, Deagostini MC, Porpiglia F, Scarpa RM. Positron emission tomography as a tool for the 'tailored' management of retroperitoneal fibrosis: a nephro-urological experience. Nephrol Dial Transplant 2010;25:2603-10. [PMID: 20157170 DOI: 10.1093/ndt/gfq051] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Dondi F, Albano D, Giubbini R, Bertagna F. PET in idiopathic retroperitoneal fibrosis. Nuclear Medicine and Molecular Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00059-4] [Reference Citation Analysis]
2 Casali M, Lauri C, Altini C, Bertagna F, Cassarino G, Cistaro A, Erba AP, Ferrari C, Mainolfi CG, Palucci A, Prandini N, Baldari S, Bartoli F, Bartolomei M, D'Antonio A, Dondi F, Gandolfo P, Giordano A, Laudicella R, Massollo M, Nieri A, Piccardo A, Vendramin L, Muratore F, Lavelli V, Albano D, Burroni L, Cuocolo A, Evangelista L, Lazzeri E, Quartuccio N, Rossi B, Rubini G, Sollini M, Versari A, Signore A. State of the art of 18F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation. Clin Transl Imaging 2021;9:299-339. [PMID: 34277510 DOI: 10.1007/s40336-021-00445-w] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 16.0] [Reference Citation Analysis]
3 Le Joncour A, Saadoun D, Cacoub P. La fibrose rétropéritonéale idiopathique. Rev Med Interne 2020;41:822-8. [PMID: 32727694 DOI: 10.1016/j.revmed.2020.06.013] [Reference Citation Analysis]
4 Peisen F, Thaiss WM, Ekert K, Horger M, Amend B, Bedke J, Nikolaou K, Kaufmann S. Retroperitoneal Fibrosis and its Differential Diagnoses: The Role of Radiological Imaging. Rofo 2020;192:929-36. [DOI: 10.1055/a-1181-9205] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
5 Morin G, Mageau A, Benali K, Bertinchamp R, Piekarski E, Raimbourg Q, Alexandra JF, Goulenok T, van Gysel D, Papo T, Sacre K. Persistent FDG/PET CT uptake in idiopathic retroperitoneal fibrosis helps identifying patients at a higher risk for relapse. Eur J Intern Med 2019;62:67-71. [PMID: 30711361 DOI: 10.1016/j.ejim.2019.01.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
6 Grozdic Milojevic IT, Milojevic B, Sobic-Saranovic DP, Artiko VM. Impact of hybrid molecular imaging in retroperitoneal fibrosis: a systematic review. Rheumatol Int 2018;38:179-87. [PMID: 28840309 DOI: 10.1007/s00296-017-3798-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
7 Wang Y, Guan Z, Gao D, Luo G, Li K, Zhao Y, Wang X, Zhang J, Jin J, Zhao Z, Yang C, Zhang J, Zhu J, Huang F. The value of 18F-FDG PET/CT in the distinction between retroperitoneal fibrosis and its malignant mimics. Semin Arthritis Rheum 2018;47:593-600. [PMID: 28958769 DOI: 10.1016/j.semarthrit.2017.07.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
8 Fernando A, Pattison J, Horsfield C, D’cruz D, Cook G, O’brien T. [ 18 F]-Fluorodeoxyglucose Positron Emission Tomography in the Diagnosis, Treatment Stratification, and Monitoring of Patients with Retroperitoneal Fibrosis: A Prospective Clinical Study. European Urology 2017;71:926-33. [DOI: 10.1016/j.eururo.2016.10.046] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
9 Jakhlal N, Elghazoui A, Jabbour Y, Karmouni T, Elkhader K, Koutani A, Ibenattya A. Fibrose rétropéritonéale: revue de littérature. Can Urol Assoc J 2017;11:E26-31. [PMID: 28163809 DOI: 10.5489/cuaj.4122] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
10 Mirault T. Malignant Diseases Mimicking Retroperitoneal and Mediastinal Fibrosing Disorders. Systemic Fibroinflammatory Disorders 2017. [DOI: 10.1007/978-3-319-41349-5_13] [Reference Citation Analysis]
11 Runowska M, Majewski D, Puszczewicz M. Retroperitoneal fibrosis - the state-of-the-art. Reumatologia 2016;54:256-63. [PMID: 27994271 DOI: 10.5114/reum.2016.63667] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
12 Kumar R, Karunanithi S, Zhuang H, Alavi A. Assessment of Therapy Response by FDG PET in Infection and Inflammation. PET Clin 2012;7:233-43. [PMID: 27157240 DOI: 10.1016/j.cpet.2012.01.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
13 Fofi C, Prosperi D, Pettorini L, Festuccia F, Pirisino R, Lanni V, Scopinaro F, Punzo G, Menè P. Diagnosis and follow-up of idiopathic retroperitoneal fibrosis: role of 18F-FDG-PET/CT and biochemical parameters in patients with renal involvement. Intern Emerg Med 2016;11:809-16. [DOI: 10.1007/s11739-016-1426-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
14 Ruhlmann V, Poeppel TD, Brandt AS, Grüneisen J, Ruhlmann M, Theysohn JM, Forsting M, Bockisch A, Umutlu L. (18)F-FDG PET/MRI evaluation of retroperitoneal fibrosis: a simultaneous multiparametric approach for diagnosing active disease. Eur J Nucl Med Mol Imaging 2016;43:1646-52. [PMID: 26969347 DOI: 10.1007/s00259-016-3351-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
15 Zhou HJ, Yan Y, Zhou B, Lan TF, Wang XY, Li CS. Retroperitoneal fibrosis: a retrospective clinical data analysis of 30 patients in a 10-year period. Chin Med J (Engl) 2015;128:804-10. [PMID: 25758277 DOI: 10.4103/0366-6999.152648] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
16 Khafagy R, Basu S, Rogawski KM. Peri-aortitis causing obstructive uropathy: a new indication for a urological follow up? Br J Hosp Med (Lond) 2012;73:712. [PMID: 23502205 DOI: 10.12968/hmed.2012.73.12.712] [Reference Citation Analysis]
17 Caiafa RO, Vinuesa AS, Izquierdo RS, Brufau BP, Ayuso Colella JR, Molina CN. Retroperitoneal Fibrosis: Role of Imaging in Diagnosis and Follow-up. RadioGraphics 2013;33:535-52. [DOI: 10.1148/rg.332125085] [Cited by in Crossref: 69] [Cited by in F6Publishing: 74] [Article Influence: 7.7] [Reference Citation Analysis]
18 Treglia G, Mattoli MV, Bertagna F, Giubbini R, Giordano A. Emerging role of Fluorine-18-fluorodeoxyglucose positron emission tomography in patients with retroperitoneal fibrosis: a systematic review. Rheumatol Int 2013;33:549-55. [PMID: 23124736 DOI: 10.1007/s00296-012-2576-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
19 Treglia G, Mattoli MV, Bertagna F. Fluorine-18-fluorodeoxyglucose positron emission tomography in assessing retroperitoneal fibrosis: a literature review. Int J Mol Imaging 2012;2012:484052. [PMID: 23050140 DOI: 10.1155/2012/484052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
20 Bertagna F, Treglia G, Leccisotti L, Bosio G, Motta F, Giordano A, Giubbini R. [¹⁸F]FDG-PET/CT in patients affected by retroperitoneal fibrosis: a bicentric experience. Jpn J Radiol 2012;30:415-21. [PMID: 22421932 DOI: 10.1007/s11604-012-0066-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
21 Treglia G, Mattoli MV, Leccisotti L, Ferraccioli G, Giordano A. Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with large-vessel vasculitis: a systematic review. Clin Rheumatol 2011;30:1265-75. [PMID: 21833685 DOI: 10.1007/s10067-011-1828-9] [Cited by in Crossref: 74] [Cited by in F6Publishing: 80] [Article Influence: 6.7] [Reference Citation Analysis]